Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: J ECT. 2013 Mar;29(1):3–12. doi: 10.1097/YCT.0b013e31826ea8c4

Figure 3.

Figure 3

Kaplan-Meier estimates of the proportion of patients who remained well during the continuation trial for patients randomized to the four treatment conditions: placebo (PL) or drug (NT or VEN) during ECT and, during continuation pharmacotherapy, nortriptyline and lithium (NT-Li) or venlafaxine and lithium (VEN-Li) as continuation pharmacotherapy.